Asthma Therapeutics Market Report 2026

The asthma therapeutics market size has grown strongly in recent years. It will grow from $33.11 billion in 2025 to $35.73 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limited availability of biologics, reliance on short-acting beta agonists, rising prevalence of asthma globally, increasing hospital and specialty clinic visits, adoption of oral and inhaled medications.

The asthma therapeutics market size is expected to see strong growth in the next few years. It will grow to $47.87 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of novel biologics and combination therapies, expansion of telemedicine and digital health monitoring, growing preventive treatment awareness, increasing healthcare access in emerging markets, rising investment in research and drug development. Major trends in the forecast period include rising adoption of personalized asthma therapies, increase in inhaler and biologic usage, expansion of homecare and remote monitoring solutions, growing preference for combination inhalers, enhanced focus on pediatric and geriatric asthma care.

The rising prevalence of asthma is anticipated to drive the growth of the asthma therapeutics market in the coming years. Asthma is a chronic condition characterized by inflammation and swelling of the airways, leading to narrowing of the passages that carry air from the nose and mouth to the lungs. The increasing incidence of asthma is largely attributed to rising levels of air pollution, which irritate the airways and increase the likelihood of developing the disease. Asthma therapeutics play a vital role in managing the condition by reducing airway inflammation, alleviating symptoms, and preventing asthma attacks. For instance, in May 2025, according to the UK Parliament, a UK-based government body, 3,886,879 individuals aged six and above were diagnosed with asthma in England during 2023-24, representing 6.5% of the population. Therefore, the growing prevalence of asthma is contributing to the expansion of the asthma therapeutics market.

Major companies operating in the asthma therapeutics market are concentrating on the development of innovative treatments, such as anti-inflammatory rescue inhalers, to improve symptom control, reduce inflammation, and enhance overall disease management. Anti-inflammatory rescue inhalers use a dual-action approach that combines a fast-acting bronchodilator with an inhaled corticosteroid in a single device, enabling rapid airway relaxation, on-demand inflammation control, and prevention of severe asthma exacerbations. For instance, in January 2024, AstraZeneca plc, a UK-based biopharmaceutical company, introduced AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler designed to provide immediate symptom relief along with rapid anti-inflammatory effects. The inhaler features as-needed dual-mechanism dosing, real-time suppression of airway inflammation, and support in reducing exacerbation-related declines in lung function. AIRSUPRA improves asthma control, lowers the risk of severe attacks, and enhances the effectiveness of rescue therapy.

In January 2025, Phillips Medisize, a US-based contract development and manufacturing organization (CDMO), acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Phillips Medisize aims to strengthen its inhalation drug delivery capabilities by incorporating Vectura’s extensive expertise in formulation and device development across dry powder inhalers, nebulizers, metered-dose inhalers, and nasal delivery systems. Vectura Group Ltd. is a UK-based company specializing in inhalation formulation, device engineering, and regulatory support services.

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asthma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the asthma therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and inhaler devices. Segments such as biologics, combination inhalers, and specialty medications are particularly affected, with regions like North America and Europe facing higher import duties. These tariffs have led to increased treatment costs and adjustments in supply chains. On the positive side, they are encouraging local manufacturing, innovation in delivery systems, and investment in domestic pharmaceutical production capabilities.

The asthma therapeutics market research report is one of a series of new reports that provides asthma therapeutics market statistics, including asthma therapeutics industry global market size, regional shares, competitors with a asthma therapeutics market share, detailed asthma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the asthma therapeutics industry. This asthma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asthma therapeutics encompass the range of medications and treatment options used to control and alleviate asthma symptoms, a chronic respiratory disorder marked by airway inflammation and narrowing. These therapies include rapid-acting medicines for immediate symptom relief as well as long-term control treatments that help reduce airway inflammation and prevent asthma exacerbations.

The main drug classes included in asthma therapeutics are inhaled corticosteroids (ICS), long-acting beta agonists, leukotriene receptor antagonists, short-acting beta agonists, biologics, and combination inhalers. Inhaled corticosteroids are medications delivered directly to the lungs to decrease inflammation and swelling in the airways, making breathing easier for individuals with asthma. They are used across different stages of treatment, including acute care, long-term control, preventive therapy, maintenance regimens, and rescue treatment, and are administered through various routes such as oral, inhaled, intravenous, and subcutaneous. These therapies are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by end users such as hospitals, home care settings, and specialty clinics.

The asthma therapeutics market consists of revenues earned by entities by providing services such as prescription management, inhaler technique training, nebulization therapy, and allergy testing and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma therapeutics market consists of sales of methylxanthines, anticholinergics, systemic corticosteroids, mast cell stabilizers, immunotherapy products, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.